Loading…
Rein Therapeutics received FDA clearance to resume its Phase 2 trial.
Rein Therapeutics, Inc. (Nasdaq: RNTX) announced on November 3, 2025, that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Phase 2 trial for LTI-03, a treatment for Idiopathic Pulmonary Fibrosis (IPF). The trial can now proceed following the resolution of the hold.
The clinical hold, which was placed earlier this year, has been lifted without any conditions, allowing the company to continue its research and development efforts for LTI-03. Rein Therapeutics has a free float of 22,628,900 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.